<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A23AF92A-1022-47A0-9EC7-7B636A203B19"><gtr:id>A23AF92A-1022-47A0-9EC7-7B636A203B19</gtr:id><gtr:name>Renishaw Plc</gtr:name><gtr:address><gtr:line1>New Mills</gtr:line1><gtr:line4>Wotton-under-Edge</gtr:line4><gtr:line5>Gloucestershire</gtr:line5><gtr:postCode>GL12 8JR</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93D8BB18-D3C0-493C-988F-E81182F1BFF9"><gtr:id>93D8BB18-D3C0-493C-988F-E81182F1BFF9</gtr:id><gtr:name>MedGenesis Therapeutix</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Clinical Science at North Bristol</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A23AF92A-1022-47A0-9EC7-7B636A203B19"><gtr:id>A23AF92A-1022-47A0-9EC7-7B636A203B19</gtr:id><gtr:name>Renishaw Plc</gtr:name><gtr:address><gtr:line1>New Mills</gtr:line1><gtr:line4>Wotton-under-Edge</gtr:line4><gtr:line5>Gloucestershire</gtr:line5><gtr:postCode>GL12 8JR</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93D8BB18-D3C0-493C-988F-E81182F1BFF9"><gtr:id>93D8BB18-D3C0-493C-988F-E81182F1BFF9</gtr:id><gtr:name>MedGenesis Therapeutix</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7037D48C-8DA5-454C-9E90-E7E60795572E"><gtr:id>7037D48C-8DA5-454C-9E90-E7E60795572E</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Philip</gtr:otherNames><gtr:surname>Lowe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BBD5D94D-6BA6-47B2-B89D-404CFF799270"><gtr:id>BBD5D94D-6BA6-47B2-B89D-404CFF799270</gtr:id><gtr:firstName>Karen</gtr:firstName><gtr:surname>Edler</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6D742CED-5C95-49BF-8C20-207A2FC57120"><gtr:id>6D742CED-5C95-49BF-8C20-207A2FC57120</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>Barua</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/31F6966F-3CD2-4586-9172-A7CF4D2FC38C"><gtr:id>31F6966F-3CD2-4586-9172-A7CF4D2FC38C</gtr:id><gtr:firstName>Sean</gtr:firstName><gtr:otherNames>Patrick</gtr:otherNames><gtr:surname>Rigby</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4B9599C8-3FEC-4ED8-BF1B-BB0409CB251A"><gtr:id>4B9599C8-3FEC-4ED8-BF1B-BB0409CB251A</gtr:id><gtr:firstName>Alison</gtr:firstName><gtr:surname>Bienemann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7807E7B0-0709-4728-B283-5B83F76D0B5D"><gtr:id>7807E7B0-0709-4728-B283-5B83F76D0B5D</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Gill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ005134%2F1"><gtr:id>561889C8-22D5-4898-B746-75B3967CD3B7</gtr:id><gtr:title>MICA: Convection-enhanced delivery of encapsulated nanospheres for controlled delivery of chemotherapy to the brain</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J005134/1</gtr:grantReference><gtr:abstractText>Glioblastoma multiforme (GBM) is the commonest primary malignant brain tumour. Despite advances in chemotherapy, radiotherapy and surgical technology, the prognosis remains poor. Only a minority of patients are suitable for maximal treatment comprising surgical excision, radiotherapy and chemotherapy, and even following maximal treatment, average survival remains at approximately 14 months from diagnosis. There is no cure for GBM and patients inevitably suffer from recurrence and progression of the disease. The majority of tumour recurrences occur within 2cm of the site of the original tumour due to microscopic invasion of tumour cells into surrounding brain tissue which escape surgical excision and radiotherapy. 

One of the major obstacles to the effective treatment of brain tumours is the existence of the blood-brain barrier (BBB), which prevents the free passage of drugs from the bloodstream into the brain. It is sometimes possible to increase the amount of drug which enters the brain by using high drug doses, but this often results in severe side-effects which are unacceptable to patients.

Our solution is to bypass the BBB by delivering chemotherapy directly to brain tissue surrounding the tumour following excision, using a neurosurgical technique called convection-enhanced delivery (CED). CED describes a method of direct drug delivery to the brain through ultrafine microcatheters. This technique allows us to target the chemotherapy to recurrent brain tumours with very high safety and accuracy, and to distribute effective drug concentrations throughout relevant areas of the brain. This approach also reduces the risk of side-effects by specifically targetting drugs to the brain. We have previously used this technique to deliver drugs to patients with Parkinson's Disease, and over the last 5 years we have been working with industrial collaborators to develop a CED catheter system which allows us to deliver repeated drug doses to the brain. 

In this project we propose to combine CED with recent advances in the field of nanotechnology. By encapsulating chemotherapies in biodegradable nanospheres our aim is to achieve controlled drug release within the brain, to reduce the drug doses required to achieve tumour regression, and to limit the risk of side-effects. We have chosen a nanosphere formulation which is widely used in the medical industry and is proven to be safe and non-toxic. We have approval for a clinical trial of CED of unencapsulated chemotherapy, and this study represents a logical progression. By using CED to deliver chemotherapy nanoparticles to the brain we hope to reduce tumour recurrence and progression and to improve the quality of life of patients with this devastating disease. 

Our research team comprises a unique collaboration between neurosurgeons, neuroscientists, chemists and chemical engineers with the knowledge and experience to develop this novel technology for patient benefit.</gtr:abstractText><gtr:technicalSummary>Our aim is to formulate biodegradable polymer-encapsulated carboplatin nanospheres suitable for convection-enhanced delivery (CED) for the treatment of recurrent/progressive Glioblastoma multiforme. The size and charge of nanospheres will be analysed using electron microscopy, dynamic light scattering and a particle zetasizer. Drug loading, size, charge and drug release profile will be optimised by manipulating such parameters as the polymer composition, synthesis conditions and extent of surface hydrolysis.

The structure and associated drug release of nanospheres will be analysed in artificial cerebrospinal fluid, PBS and saline using atomic absorption spectroscopy (AAS), and nuclear magnetic resonance (NMR) relaxometry and cryoporometry. The cytotoxic efficacy of carboplatin nanospheres will be compared to unencapsulated carboplatin in human glioma and neuronal cultures. This will allow us to select the optimum formulation and vehicle for in vivo testing of CED of nanospheres.

The distribution, half-life and toxicity of nanospheres delivered by CED will be studied in vivo. Catheters will be stereotactically inserted into the brain and distribution analysed using fluorescently-labelled nanospheres. The in vivo clearance, half-life and stability of platinum released from nanospheres will be assessed using AAS and liquid chromatography-mass spectrometry. The toxicity of chemotherapy nanospheres will be compared to unencapsulated carboplatin by analysing the extent of astrocytosis, pre-and post-synaptic proteins and neuronal content.

On the basis of in vitro testing of loading efficiency, charge, size and drug release profile as well as in vivo analysis of distribution, half-life and toxicity in a small animal model we will progress to in vivo testing in a large animal model. We will perform intermittent drug delivery at intervals determined by clearance studies using a chronic in-dwelling CED catheter system in order to complete a dose-escalation study</gtr:technicalSummary><gtr:potentialImpactText>The outcomes of this research project are likely to have a number of economic and societal implications resulting in a number of non-academic beneficiaries both in the short and long-term.

Short-term beneficiaries:
1. The pharmaceutical industry
One of the major aims of this study is to combine advances in convection-enhanced drug delivery technology with the use of nanoformulations. Such a treatment strategy has applications for a range of neuro-therapeutics. We envisage that a successful outcome in this study will attract R&amp;amp;D investment from the pharmaceutical industry which will facilitate rapid translation to clinical trials. The Functional Neurosurgery Research Group has on-going collaborations with a number of US and European pharmaceutical biotechnology companies who also stand to benefit from success in this study. A second major aim is the development of a biocompatible nanoscale drug delivery platform which facilitates controlled drug release over a prolonged period. Such a system has applications for a range of therapeutic agents.

2. UK medical device and nanotechnology regulators
The Medical and Healthcare Regulatory Agency (MHRA) has been actively involved in aiding our research group to obtain approval for clinical trials of CED for both neuro-oncological and neurodegenerative disorders. The MHRA is also committed to monitoring the progress of nanotechnology in healthcare. Successful outcomes from this study and rapid progression to subsequent clinical trials could provide a model for safe and effective translational research in the rapidly expanding field of nanomedicine.

3. Renishaw Plc. (Industrial Collaborators)
The chronic intermittent catheter systems described in this proposal are manufactured by our industrial collaborators. This study has the potential to validate use of this device for chronic intermittent delivery of nanoparticles. Industrial collaboration is paramount for effective translation of this therapeutic strategy to clinical trials, for large-scale production of catheter systems and for collaboration with the pharmaceutical industry. Success in this study is likely to attract further R&amp;amp;D investment from pharmaceutical collaborators and to promote the sustainability of the business, in particular, Renishaw's Neurological Products Division. 

4. The general public
Successful results relating to the safety and toxicity of the nanoformulations used in this study are likely to increase public confidence in emerging nanotechnologies and their application to nanomedicine. We plan to contribute to the debate by providing scientifically rigorous content for websites, the press and public science events.

Longer-term beneficiaries:
5. Patients with recurrent/progressive Glioblastoma Multiforme.
The ultimate aim of this research is to facilitate a phase I clinical trial of convection-enhanced delivery of biodegradable polymer-encapsulated carboplatin nanospheres for recurrent/progressive GBM. By delivering the therapeutic agent to peritumoral tissue our aim is to target invasive tumour cells which escape surgical resection and the field of radiotherapy, and thereby reduce the risk of tumour recurrence/progression. By encapsulating chemotherapy in polymeric nanospheres our aim is to reduce the overall dose required and the frequency of dosing, reduce side-effects and also the development of resistance to chemotherapy. 

6. The National Health Service
By encapsulating chemotherapy within nanospheres we aim to achieve prolonged drug release within the brain, and thereby reduce the frequency of drug administration without impairing clinical efficacy. The chronic intermittent drug delivery system is designed to allow patients to receive drug infusions on a day case basis, which we envisage will prevent the need for inpatient admission. The reduced requirement for hospital attendance may reduce NHS in patient costs and will also improve our patients' quality of life.</gtr:potentialImpactText><gtr:fund><gtr:end>2013-11-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-30</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>597390</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>MedGenesis Therapeutix</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>GDNF Pre-clinical and Phase II trials</gtr:description><gtr:id>0CFE574E-9827-4647-B7DD-B72B10EE54D1</gtr:id><gtr:impact>publication and knowledge to be carried forward in the upcoming clinical trial</gtr:impact><gtr:outcomeId>NNyJew2nkoC-1</gtr:outcomeId><gtr:partnerContribution>The purpose of this study is to establish the optimum concentration of infused GDNF to achieve synaptogenesis and axonal sprouting (markers of neurorestoration) and to quantify the biological half-life of GDNF to determine an appropriate dosing frequency.</gtr:partnerContribution><gtr:piContribution>Research partner</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry Nottingham</gtr:department><gtr:description>University of Notttingham</gtr:description><gtr:id>141A806F-246B-493D-903F-49BA69F06544</gtr:id><gtr:impact>Improved drug release profile to continue the project.</gtr:impact><gtr:outcomeId>aNa8Aq26jYB-1</gtr:outcomeId><gtr:partnerContribution>In collaboration we have achieved milestone one and improvements can be made to the drug release profile to continue the project.</gtr:partnerContribution><gtr:piContribution>Specialised techniques and expertise from the team in Chemistry has allowed a sucesful collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Renishaw plc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Surgical Equipment</gtr:description><gtr:id>0AECD316-E14D-49D5-A16E-C9CBBBACB0AF</gtr:id><gtr:impact>Collaboration with medical engineering company to develop drug delivery equipment for use in humans.</gtr:impact><gtr:outcomeId>589B70A8E12-1</gtr:outcomeId><gtr:partnerContribution>Renishaw have provided stereotactic surgical equipment that have allowed us to undertake experiments in large animals.</gtr:partnerContribution><gtr:piContribution>We have evaluated their drug delivery equipment in large animal models.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>University of Bath</gtr:description><gtr:id>84C97BB8-F9CE-4B3A-95CD-FBF47131336F</gtr:id><gtr:impact>Ongoing reached milesone one at present, now onwards to the next milestone</gtr:impact><gtr:outcomeId>pLZ2AESWquW-1</gtr:outcomeId><gtr:partnerContribution>Chemical knowledge in formulation of nanoparticles</gtr:partnerContribution><gtr:piContribution>MRC grant subcontract to supply /formulate nanocomplexes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Conference (2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>328868F9-63C1-4C5E-A1D3-660D1E033884</gtr:id><gtr:impact>February 2015
Development of a stable platform for Convection- Enhanced Delivery of chemotherapy for Glioma. III Memorial &amp;quot;Alicia Pueyo&amp;quot; DIPG Workshop, Barcelona</gtr:impact><gtr:outcomeId>56e1464a3143b1.47531065</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> International Symposium on Neural Transplantation 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5993A2B6-3B94-4C67-B7C0-58E274D33E3C</gtr:id><gtr:impact>? 12th International Symposium on Neural Transplantation 
o Key note speaker GDNF -Back in the clinic
o Held in Cardiff, Wales.UK
o 3rd-6th September 2013



Sharing knowledge with fellow peers</gtr:impact><gtr:outcomeId>tL2McW5jzjZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>(2015) Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>67BFF83B-0B4E-47A1-BCDD-34BBE88F25E1</gtr:id><gtr:impact>Amsterdam, April 2015 SIOPE HGG/DIPG business meeting, 
A phase I/II dose-escalation study of intermittent convection-enhanced delivery of carboplatin and topotecan for diffuse intrinsic pontine glioma (DIPG) in children and young adults:</gtr:impact><gtr:outcomeId>56e146d72bc1e1.41568284</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.dkfz.de/de/aktuelles/download/HeidelbergSIOP-BTG-Program-V8-SMP-rutk-18-05-15.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>(2015) Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EA88DDB2-0EA3-4365-B0D6-12255CCBF04A</gtr:id><gtr:impact>November 2015 Texas USA Clinical Experience with an Intermittent Drug Delivery Device</gtr:impact><gtr:outcomeId>56e1477174dea5.34441043</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.soc-neuro-onc.org/cns-therapeutic-delivery-conference/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>03946BBB-0E09-4592-9F2E-BCD9C4B6DA40</gtr:id><gtr:impact>Drug Delivery in Paediatric Brain Tumours Conference 
The first Workshop on Drug Delivery in Paediatric Brain Tumours was hosted in London by the charity Children with Cancer UK. The goals of the workshop were to break down the barriers to treating central nervous system (CNS) tumours in children, leading to new collaborations and further innovations in this under-represented and emotive field. These barriers include the physical delivery challenges presented by the blood-brain barrier, the underpinning reasons for the intractability of CNS cancers, and the practical difficulties of delivering cancer treatment to children. Novel techniques for overcoming these problems were discussed, new models brought forth, and experiences compared.

Keywords: Drug delivery, translational medicine, paediatrics, brain tumours, glioma, medulloblastoma, CNS involvement, blood-brain barrier</gtr:impact><gtr:outcomeId>58c7bb43308ad0.27908205</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://ecancer.org/conference/articles/831-drug-delivery-in-paediatric-brain-tumours.php</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>(2015) Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8B72B123-22B7-42F7-956C-F03A49C4943C</gtr:id><gtr:impact>Annual Congress of International Drug Discovery Science &amp;amp; Technology -)</gtr:impact><gtr:outcomeId>56e14848a13a41.41541802</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.iddst.com/iddst2014/price.asp</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference British  NeuroOncology Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>37877139-F55D-4199-BAE9-3B7014770188</gtr:id><gtr:impact>Conference stimulated around our poster presentations and presentation

Interest and potential collaboration was gathered</gtr:impact><gtr:outcomeId>5464c8b369d444.71632670</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.bnos.org.uk/conference.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>3rd Targeted Drug Delivery for Pain and Neurologic Disease</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>967AFF0A-A47D-495C-B720-BA9F4002EC0D</gtr:id><gtr:impact>? The 3rd Targeted Drug Delivery for Pain and Neurologic Disease SSG
o Speaker
o Held in San Francisco, CA. USA
o May 3 - 5, 2013

I gave a talk about the upcoming clinical trials</gtr:impact><gtr:outcomeId>sKhRDH1iyXU</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Childrens Cancer and Leukaemia Group - Radiation Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D4DDD941-C0FA-4BC4-BCCE-7D19DA9CFA36</gtr:id><gtr:impact>? Childrens Cancer and Leukaemia Group - Radiation Meeting 
o Speaker
o Bristol
o June 2013


Meeting and forming collaborations</gtr:impact><gtr:outcomeId>b2GJAvvT6p9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Functional Neurosurgery in Bristol</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A201581B-FA60-409C-8614-CCDD64D0B6D1</gtr:id><gtr:impact>Presnentation of CED to fellow surgeons

Fellow functional neurosurgeons</gtr:impact><gtr:outcomeId>qP1d7wXZTCC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Society of Stereotactic and Functional Neurosurgery (2013)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>67FBE4EA-6553-4B43-8BFA-B20333906403</gtr:id><gtr:impact>? World Society of Stereotactic and Functional Neurosurgery (WSSFN) SSG
o Speaker 
o held in Tokyo, Japan
o from May 27- 30, 2013.


I gave a talk with regard to our experiences with techniques of direct intracranial drug delivery.</gtr:impact><gtr:outcomeId>kFrwzPBBaro</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Developing an Auto-pilot for Functional Neurosurgery 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>521F2BFD-C576-4A62-BF57-825EA2BCC1E9</gtr:id><gtr:impact>Developing an Auto-pilot for Functional Neurosurgery 18/10/13

Excellent group session for those that attended</gtr:impact><gtr:outcomeId>tAQnisiefRE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nanotechnologies in Cancer Diagnosis, Therapy and Preventions 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>41CB44C9-EB13-4A8D-8A28-323CA58C8C0E</gtr:id><gtr:impact>? Nanotechnologies in Cancer Diagnosis, Therapy and Preventions AA
o Poster
o Held in New York
o June 11-13, 2013


Excellent networking potential for members of my research group</gtr:impact><gtr:outcomeId>tscjUtWUwRj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Image guided surgery for Orthopaedic surgeons/. Medtronic</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DB37CE3A-6863-49C4-AE28-AE10209E862C</gtr:id><gtr:impact>? Image guided surgery for Orthopaedic surgeons/. Medtronic SSG
o Speaker
o Held in Edinburgh, Scotland.UK
o 16th 17th June 2013 


Technology sharing exercise</gtr:impact><gtr:outcomeId>o2k7SMyugi3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sky News (2013)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7D9ACA2D-B6E1-4B02-ADB5-2A6A046DDC10</gtr:id><gtr:impact>Interview with SKY news

Scientists in Bristol have developed a system of tubes and catheters that allows them to pump protein therapy deep into patients' brains.</gtr:impact><gtr:outcomeId>MKgjgKG4Txv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://news.sky.com/story/1153456/brain-implant-could-stop-parkinsons-growth</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mending Brains with Parkinson's Disease 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F58A32E5-519A-47EE-B9B0-62FFFDC07E85</gtr:id><gtr:impact>Local Charity event to raise the profile and fund raise for the upcoming clinical trials</gtr:impact><gtr:outcomeId>gCfeKAnU8Sn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference  (Milan)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D82F234A-65AF-43F9-A6A9-EE97081F8560</gtr:id><gtr:impact>Conference SIOP European Society for Paediatric Oncology November 21-26 2016
 Working group Meeting to include international experts in the field. Focus on biospy in DIPG and the future for research.</gtr:impact><gtr:outcomeId>58c7bccad90653.18929995</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.siope.eu/wp-content/uploads/2014/03/20160930_PreliminaryAGENDA_Milano_SIOPE-HGG_DIPG-Working-Group-Meeting.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> Conference   nano tek</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0DA29050-A7C6-42B5-AA70-8C262F76C891</gtr:id><gtr:impact>Excellent reception to our data presented

A number of collaborators were gained after this conference</gtr:impact><gtr:outcomeId>5464ca99c677c0.30515191</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://nanotechnology2014.conferenceseries.net/cfa.php</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Local News (2013)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D8EA3559-4D15-4ABD-AC52-A62BA83DBA39</gtr:id><gtr:impact>A pilot into the treatment of Parkinson's disease which researchers hope could help to slow down the condition is taking place in Bristol.

Updating on sucess</gtr:impact><gtr:outcomeId>dGzg9mbDDtL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/uk-england-bristol-24456415</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>First Hammer Out Patient/Carer Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6384323F-F87F-4BFC-9DA0-79E764679FC9</gtr:id><gtr:impact>I gave a talk to patients and carers of patients with primary brain tumours regarding our research into new techniques and treatments for brain tumours.

Nil.</gtr:impact><gtr:outcomeId>76D9377F81D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC MR/J005134/1. Convection-enhanced delivery of encapsulated nanosperes for controlled delivery of chemotherapy to the brain</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F0CAC131-1D61-4FFB-9CF9-2EC714661359</gtr:id><gtr:outcomeId>SbCoU9uWLiN0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Glioblastoma is an untreatable from of brain tumour. Treatment by surgery or chemotherapy fails to prevent tumour recurrence and progression, leading to inevitable death. Previous studies have demonstrated that the majority of recurrences occur within 2cm of the original tumour site, indicating that the major cause of recurrence is microscopic tumour invasion into peritumoral brain tissue. The unmet need addressed by this invention is to target encapsulated chemotherapy nanospheres to peritumoral brain tissue in order to reduce the incidence of tumour recurrence and to prolong disease-free survival

This invention builds upon extensive experience at NBT / UoB in Convection Enhanced Delivery (CED). CED is a means of delivering controlled quantities of drug directly into the brain using in-dwelling catheters and carefully controlled concentration / pressure gradients. This methodology has been developed over the past 10 years by Professor Stephan Gill in collaboration with Renishaw Plc. His team are currently treating malignant brain tumours in adult and paediatric patients with CED of carboplatin. This treatment strategy is based upon substantial pre-clinical and clinical data suggesting carboplatin directly delivered to brain tumours could be effective in controlling disease progression. However, CED of free carboplatin has a number of limitations that the current invention seeks to overcome. These include:

- Carboplatin is not specifically toxic to tumour cells and could therefore result in neurotoxicity
- Carboplatin is cleared from the brain relatively quickly following CED. Consequently it is necessary to perform repeat infusions over 2 to 3 days in order to maintain exposure of the tumour to therapeutic drug concentrations.

Over the past 15 months the team have been working in collaboration with the Universities of Bath and Nottingham to develop and test the encapsulation of carboplatin in Polylactide-co-glycolide (PLGA) nanospheres / nanoparticles, with the specific aim of addressing the above limitations. PLGA is an FDA-approved biodegradable and biocompatible co-polymer used widely in the pharmaceutical industry. Through CED pilot studies the team have been able to devised a number of criteria in relation to nanosphere formulation and characteristics with the aim of developing carboplatin/PLGA nanospheres optimised for CED. To the best of our knowledge this is the first time carboplatin/PLGA nanospheres have been formulated specifically for delivery by CED for the treatment of brain tumours. 

In summary, the invention is a specific formulation of carboplatin/PLGA therapy for use in combination with CED for the treatment of brain tumours.</gtr:description><gtr:grantRef>MR/J005134/1</gtr:grantRef><gtr:id>8C73D14F-F5BC-44A8-A0AF-5A08ED3A5438</gtr:id><gtr:impact>The potential impact on covering our novel aspect, data generated from this grant application</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>bFQKeD7duGc</gtr:outcomeId><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>Patent Filed Ref P117522GB - Your ref: CED</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Milestone Meetings</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>676DCF0B-0B37-4A5C-B2EC-45B68493472F</gtr:id><gtr:outcomeId>XJvyT34ou7T</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>The knowledge gained from the Profesor Steven Gill research and clinical teams here at Bristol has allowed the successful development of Catheters in collaboration with Renishaws for the upcoming clinical trials</gtr:description><gtr:id>8D4A70BA-EE0A-4C66-A27F-CF7826CF3E00</gtr:id><gtr:impact>Future treatment will become less invasive</gtr:impact><gtr:outcomeId>oyHK9P4v12i</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CED for  the treatment of Oncology  and Neuro degenerative disease</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Development /collaboration to analyze samples to enable improvements to be made for the nanoparticles prior to in vivo testing</gtr:description><gtr:id>DB2B2AB8-535F-4DD2-AA12-E7AD2FC65799</gtr:id><gtr:impact>Quantitative data sampling</gtr:impact><gtr:outcomeId>LXwUAkJqSxx</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>AAS</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Laser Detection for ongoing projects in collaboration with Sheffield university</gtr:description><gtr:id>7873CF95-5E4F-4A65-9C93-7F255DA32B2C</gtr:id><gtr:impact>Excellent detection of Carboplatin, involved in this research</gtr:impact><gtr:outcomeId>WQZzWTYzrkB</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>LA-ICP-MS</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Inductively coupled plasma mass spectrometry (ICP-MS) is a type of mass spectrometry which is capable of detecting metals and several non-metals at concentrations as low as one part in 1012 (part per trillion). Used .for ongoing projects in collaboration with Sheffield university</gtr:description><gtr:id>94FE9C4B-C6DB-4666-8D3D-E36F977AA485</gtr:id><gtr:impact>Excellent quantitative results obtained.</gtr:impact><gtr:outcomeId>LjDPNthidWF</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ICP-MS</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0781DD0C-C44C-4075-95F6-83D777435CAA</gtr:id><gtr:title>Intermittent convection-enhanced delivery to the brain through a novel transcutaneous bone-anchored port.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46a353232dc6e1939e713f411c4236f4"><gtr:id>46a353232dc6e1939e713f411c4236f4</gtr:id><gtr:otherNames>Barua NU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>pm_16323_23_23419699</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BC757C8-A8BB-4648-9AF9-DA3C430D10C8</gtr:id><gtr:title>Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6f4e9cea913b477edebe9457cdfb5bc"><gtr:id>a6f4e9cea913b477edebe9457cdfb5bc</gtr:id><gtr:otherNames>Killick-Cole CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5aa7bd277d80a8.72596473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92E9138F-43F0-4572-BA80-7EA8B3C8E1EB</gtr:id><gtr:title>NMR cryoporometry characterisation studies of the relation between drug release profile and pore structural evolution of polymeric nanoparticles.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ff03e6b6e0dde5a07b902c0c3e0bf54"><gtr:id>8ff03e6b6e0dde5a07b902c0c3e0bf54</gtr:id><gtr:otherNames>Gopinathan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn><gtr:outcomeId>58c7d6da015020.36643026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35A92CFF-037D-42E0-A72C-91381D19FB35</gtr:id><gtr:title>Convection-enhanced drug delivery: prospects for glioblastoma treatment.</gtr:title><gtr:parentPublicationTitle>CNS oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46a353232dc6e1939e713f411c4236f4"><gtr:id>46a353232dc6e1939e713f411c4236f4</gtr:id><gtr:otherNames>Barua NU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2045-0907</gtr:issn><gtr:outcomeId>54624bac9a9913.48488187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83188953-3DF3-4069-8965-762044560BFF</gtr:id><gtr:title>Convection-Enhanced Delivery of Carboplatin PLGA Nanoparticles for the Treatment of Glioblastoma.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bd092d91f8a11a1e0a9c0de40b9e524"><gtr:id>2bd092d91f8a11a1e0a9c0de40b9e524</gtr:id><gtr:otherNames>Arshad A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675e8b7568e6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>673C9586-E32B-4468-B059-FFFD808E2F75</gtr:id><gtr:title>Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a416d94c60a867fb3cccff5217f2c8f4"><gtr:id>a416d94c60a867fb3cccff5217f2c8f4</gtr:id><gtr:otherNames>Patel NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16323_23_23946313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52F06AFB-44A8-48F0-89CC-239615169C25</gtr:id><gtr:title>Small angle neutron scattering studies on the internal structure of poly(lactide-co-glycolide)-block-poly(ethylene glycol) nanoparticles as drug delivery vehicles.</gtr:title><gtr:parentPublicationTitle>Biomacromolecules</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fd119054dfaef103e300b55a14de1c3"><gtr:id>5fd119054dfaef103e300b55a14de1c3</gtr:id><gtr:otherNames>Yang B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-7797</gtr:issn><gtr:outcomeId>doi_55faa2aa246c920e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AC11B01-16C1-42C9-B62C-52CF47D49B67</gtr:id><gtr:title>In vitro and in vivo testing of a novel recessed-step catheter for reflux-free convection-enhanced drug delivery to the brain.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fa8bb3dc089650e65e1b5905831d7a1"><gtr:id>2fa8bb3dc089650e65e1b5905831d7a1</gtr:id><gtr:otherNames>Gill T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>pm_16323_23_23835009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E565F236-BFFC-4920-B553-A5A1EB01068F</gtr:id><gtr:title>A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma.</gtr:title><gtr:parentPublicationTitle>Drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46a353232dc6e1939e713f411c4236f4"><gtr:id>46a353232dc6e1939e713f411c4236f4</gtr:id><gtr:otherNames>Barua NU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1071-7544</gtr:issn><gtr:outcomeId>54624bac712647.33585174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA3DE50E-337D-4C8D-98A8-8F7DF5092CBA</gtr:id><gtr:title>Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem glioma.</gtr:title><gtr:parentPublicationTitle>Acta neurochirurgica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46a353232dc6e1939e713f411c4236f4"><gtr:id>46a353232dc6e1939e713f411c4236f4</gtr:id><gtr:otherNames>Barua NU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6268</gtr:issn><gtr:outcomeId>pm_16323_23_23595829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28A44773-0C1E-4AA7-8954-716F696FE946</gtr:id><gtr:title>Convection-enhanced delivery of AAV2 in white matter--a novel method for gene delivery to cerebral cortex.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46a353232dc6e1939e713f411c4236f4"><gtr:id>46a353232dc6e1939e713f411c4236f4</gtr:id><gtr:otherNames>Barua NU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>pm_16323_23_23988614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0545E6D4-546C-4665-AAC0-8EFB4339A992</gtr:id><gtr:title>Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains.</gtr:title><gtr:parentPublicationTitle>American journal of translational research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff7aa49de9168b62f11f95bc6701619d"><gtr:id>ff7aa49de9168b62f11f95bc6701619d</gtr:id><gtr:otherNames>Tsujiuchi T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54624bac3b5321.99333393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11DA0913-9D66-454B-B5DE-5C9FAD84FD87</gtr:id><gtr:title>Chronic, intermittent convection-enhanced delivery devices.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87d18f84b50193661612b82546af92c1"><gtr:id>87d18f84b50193661612b82546af92c1</gtr:id><gtr:otherNames>Lewis O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>56d6cc2dbaa480.74494516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A32A638-BA32-444B-9C0B-9E1FF96152D4</gtr:id><gtr:title>Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model.</gtr:title><gtr:parentPublicationTitle>International journal of nanomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/672472503ff42235b331a15f3ba9b375"><gtr:id>672472503ff42235b331a15f3ba9b375</gtr:id><gtr:otherNames>Singleton WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1176-9114</gtr:issn><gtr:outcomeId>58c7d772cef792.33501388</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J005134/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>